Type
. The evaluation of present antileprosy compounds. Advances in pharmacology and chemotherapy. 1969;7:211-51.
Type
. Cell-mediated immunological processes in leprosy. Bulletin of the World Health Organization. 1969;41(6):779-92.
Type
. New prospects for the study of leprosy in the laboratory. Bulletin of the World Health Organization. 1969;40(5):785-800.
Type
. Maintenance of infectivity of M. lepraemurium in vitro for sixteen years by means of lyophilization. Determination by bacteriologic and morphologic observation of the infecting bacilli. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 1969;37(1):64-7.
Type
. Study of the ribosomes of Mycobacterium lepraemurium. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 1969;37(1):52-63.
Type
. Chemotherapeutic trials in leprosy. 7. Trial of 50 mgm. DDS twice weekly in the treatment of lepromatous leprosy. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 1969;37(1):40-5.
Type
. Correlation of histopathologic changes in the liver and bone marrow of leprosy patients. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 1969;37(1):28-39.
Type
. Chemotherapy of leprosy. Annual review of pharmacology. 1969;9:37-50.
Type
. Second trial of low dosages of DDS in lepromatous leprosy. Leprosy review [Internet]. 1969;40(1):54-8. Available from: http://leprev.ilsl.br/pdfs/1969/v40n1/pdf/v40n1a08.pdf
Type
. G 30 320 or B 663--lampren (Geigy). Leprosy review [Internet]. 1969;40(1):21-47. Available from: http://leprev.ilsl.br/pdfs/1969/v40n1/pdf/v40n1a06.pdf